Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase.
作者信息
Chakraborty S, Lin Y-H, Leng X, Miranda R N, Medeiros L J, Shpall E, Arlinghaus R B
机构信息
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Blood Cancer J. 2013 Sep 6;3(9):e142. doi: 10.1038/bcj.2013.41.
Abstract
摘要
相似文献
1
Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase.
Blood Cancer J. 2013 Sep 6;3(9):e142. doi: 10.1038/bcj.2013.41.
2
Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.
Oncogene. 2009 Apr 9;28(14):1669-81. doi: 10.1038/onc.2009.7. Epub 2009 Feb 23.
3
Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML).
Genes Cancer. 2010 Apr;1(4):346-59. doi: 10.1177/1947601910372232.
4
Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis.
Leuk Res. 2006 Oct;30(10):1323-4. doi: 10.1016/j.leukres.2005.12.006. Epub 2006 Jan 26.
5
The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and gene fusion presenting as B-lymphoblastic leukemia.
Cold Spring Harb Mol Case Stud. 2020 Apr 1;6(2). doi: 10.1101/mcs.a004937. Print 2020 Apr.
6
Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):121-5. doi: 10.1016/j.bcmd.2013.09.002. Epub 2013 Oct 3.
7
8
Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells.
Nat Med. 2004 Nov;10(11):1187-9. doi: 10.1038/nm1127. Epub 2004 Oct 24.
9
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
Blood. 2003 Jan 15;101(2):690-8. doi: 10.1182/blood.V101.2.690.
10
Concurrent megakaryocytic and erythroid chronic myelogenous leukemia blast crisis.
Arch Pathol Lab Med. 2008 Jun;132(6):1021-5. doi: 10.5858/2008-132-1021-CMAECM.
引用本文的文献
1
Methods for Design of Kinase Inhibitors as Anticancer Drugs.
Front Chem. 2020 Jan 8;7:873. doi: 10.3389/fchem.2019.00873. eCollection 2019.
2
Lyn mediates FIP1L1-PDGFRA signal pathway facilitating IL-5RA intracellular signal through FIP1L1-PDGFRA/JAK2/Lyn/Akt network complex in CEL.
Oncotarget. 2016 Aug 19;8(39):64984-64998. doi: 10.18632/oncotarget.11401. eCollection 2017 Sep 12.
3
Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia.
Genes Cancer. 2016 May;7(5-6):201-208. doi: 10.18632/genesandcancer.111.
4
Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia.
Leuk Res Treatment. 2015;2015:757694. doi: 10.1155/2015/757694. Epub 2015 Dec 3.
5
HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells.
Genes Cancer. 2015 Jan;6(1-2):19-29. doi: 10.18632/genesandcancer.49.
6
c-Abl activates janus kinase 2 in normal hematopoietic cells.
J Biol Chem. 2014 Aug 1;289(31):21463-72. doi: 10.1074/jbc.M114.554501. Epub 2014 Jun 12.
本文引用的文献
1
Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.
Leukemia. 2011 Mar;25(3):463-72. doi: 10.1038/leu.2010.287. Epub 2010 Dec 24.
2
Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.
Oncogene. 2009 Apr 9;28(14):1669-81. doi: 10.1038/onc.2009.7. Epub 2009 Feb 23.
3
Janus kinase 2: a critical target in chronic myelogenous leukemia.
Cancer Res. 2006 Jul 1;66(13):6468-72. doi: 10.1158/0008-5472.CAN-06-0025.
4
Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells.
Nat Med. 2004 Nov;10(11):1187-9. doi: 10.1038/nm1127. Epub 2004 Oct 24.
5
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.
Cancer Res. 2004 Jan 15;64(2):672-7. doi: 10.1158/0008-5472.can-03-1484.
6
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Science. 2001 Aug 3;293(5531):876-80. doi: 10.1126/science.1062538. Epub 2001 Jun 21.
Zotero 插件